Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811848 | 0.87 | CYP1A2 (0.31) | CYP4F2CYP4A11CYP1A2HPGD | |
| SCHEMBL30811764 | 0.84 | CYP4F2 (0.33) | CYP4F2CYP4A11CYP1A2HPGD | |
| SCHEMBL30811693 | 0.80 | RXRA (0.37) | CYP4F2CYP4A11CYP1A2HPGDRXRA | |
| SCHEMBL2144587 | 0.75 | GAA (0.38) | CYP4F2CYP4A11CYP1A2HPGD | |
| SCHEMBL27338781 | 0.75 | MAPT (0.40) | CYP4F2CYP4A11CYP1A2HPGD | |
| SCHEMBL2144649 | 0.73 | CYP4F2 (0.35) | CYP4F2CYP4A11CYP1A2HPGD | |
| SCHEMBL18260860 | 0.69 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31085432 | 0.69 | MAPT (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL22655613 | 0.69 | MAPT (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29176199 | 0.69 | RXRA (0.38) | CYP4F2CYP4A11CYP1A2HPGDRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720533-A | MetTL3 inhibitor compound and pharmaceutical composition and application thereof | 北京华益健康药物研究中心 | 2024-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | CYP4F2 235/4885CYP4A11 233/4885CYP1A2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.